Article Figures & Data
Figures
- FIGURE 1.
TCR Vβ repertoire in CD8 cells from normal cord blood: Immunoscope pattern shows no clonal dominance. A–L indicate reaction sets of multiplex PCRs (see Table II).
- FIGURE 2.
Representative immunoscope pattern of CD8 TCR Vβ repertoire showing major clonal dominance in CD8 cells from an HIV-infected child. Arrowheads indicate dominant clones that appear as single peaks to reflect clonal dominance in affected Vβ families. A–L indicate reaction sets of multiplex PCRs (see Table II).
- FIGURE 3.
Lymphoproliferative responses in HIV-infected children. LPAs were performed with PBMCs as described in Materials and Methods. Patient group 1 = major/minor clonal dominance; patient group 2 = single/no clonal dominance. ∗, Mean stimulation index values in group 1 were significantly higher than in group 2 (p = 0.002 for Candida and tetanus responses and p < 0.001 for responses to alloantigens).
- FIGURE 4.
Correlation between the number of CD8 TCR Vβ-dominant clones and the percentage of CD4 cells in HIV-infected children (r = 0.669, p < 0.001).<./>
- FIGURE 5.
Correlation between the number of CD8 TCR Vβ-dominant clones and plasma HIV RNA in HIV-infected children. There is no statistically significant correlation (r = −0.236, p = 0.285).
Tables
Subject ID No. Pattern of Dominancec Dominant Vβ Family(s) HIV RNA Copies/ml (log10) Age (yr) CDC Class CD4 % CD8 % ARTa Group 1 964 Major 4, 1, 12, 22 <200 (<2.3) 1.1 N1 31 32 Yes 860 Major 1, 2, 3, 5.2, 7, 22, 11, 15 43,575 (4.6) 1.6 C1 34 45 Yes 677 Major 5.1, 15, 9 9,408 (3.9) 4 B1 40 35 Yes 121 Major 19, 5.1, 5.2, 11, 12, 8 9,068 (3.9) 5 C1 25 42 Yes 117b Major 23, 2, 14, 24, 16, 9 58,812 (4.9) 7 N1 43 33 No 569 Major 2, 14, 21, 15 648,678 (5.8) 8.4 B3 3 58 Yes 804b Major 2, 5.1, 7, 17, 14 20,160 (4.3) 9 N1 30 37 No 113 Major 24, 3, 13.1, 16, 20 1,486 (3.1) 11 B1 26 44 Yes 129 Major 6, 7, 17 4,574 (3.6) 13 A1 37 46 Yes 988 Major 18, 3, 19, 14 394,156 (5.6) 13.5 A3 10 23 Yes 1075 Minor 2, 5.2 1,039 (3.0) 0.75 N1 30 22 Yes 114 Minor 6, 22 76,509 (4.8) 5.4 C1 30 42 No Group 2 992 Single 1 89,639 (4.9) 7.5 B3 9 67 Yes 658 Single 18 50,099 (4.6) 8.3 B3 2 47 Yes 109 Single 7 67,037 (4.8) 9.4 B3 7 34 Yes 1028 None — 25,571 (4.4) 5.4 B3 7 28 Yes 124 None — 131,924 (5.1) 6.0 B3 17 56 Yes 108 None — 53,772 (4.7) 9.6 B3 9 65 Yes 029 None — 21,888 (4.3) 10.4 B3 12 21 Yes 675 None — 2,022 (3.4) 12.6 B3 14 48 Yes 780 None — 531,429 (5.7) 14 A3 7 50 Yes 962 None — 94,356 (4.9) 15 C3 2 59 Yes a ART with dual or triple drug combinations including AZT, 3TC, ddI, d4T, Nevirapine, and the protease inhibitors Nelfinavir, Ritonavir, and Saquinavir.
b Patients identified as LTNPs.
c Major = three or more Vβ families involved, minor = two Vβ families, single = one Vβ family, none = no clonal dominance.
Primer Sequence Position Reaction Seta Vβ1 5′-CAA CAG TTC CCT GAC TTG CAC-3′ 84 A Vβ2 5′-TCA ACC ATG CAA GCC TGA CCT-3′ 86 B Vβ3 5′-TCT AGA GAG AAG AAG GAG CGC-3′ 86 C Vβ4 5′-CAT ATG AGA GTG GAT TTG TCA TT-3′ 122 B Vβ5S1 5′-TTC AGT GAG ACA CAG AGA AAC-3′ 135 D Vβ5S2 5′-CCT AAC TAT AGC TCT GAG CTG-3′ 75 D Vβ6 5′-AGG CCT GAG GGA TCC GTC TC-3′ 81 E Vβ7 5′-CTG AAT GCC CCA ACA GCT CTC-3′ 86 F Vβ8 5′-TAC TTT AAC AAC AAC GTT CCG-3′ 144 B Vβ9 5′-AAA TCT CCA GAC AAA GCT CAC-3′ 84 G Vβ10 5′-CAA AAA CTC ATC CTG TAC CTT-3′ 76 L Vβ11 5′-ACA GTC TCC AGA ATA AGG ACG-3′ 90 H Vβ12 5′-GAC AAA GGA GAA GTC TCA GAT-3′ 117 H Vβ13S1 5′-GAC CAA GGA GAA GTC CCC AAT-3′ 117 C Vβ13S2 5′-GTT GGT GAG GGT ACA ACT GCC-3′ 135 I Vβ14 5′-TCT CGA AAA GAG AAG AGG AAT-3′ 84 J Vβ15 5′-GTC TCT CGA CAG GCA CAG GCT-3′ 87 I Vβ16 5′-GAG TCT AAA CAG GAT GAG TCC-3′ 132 G Vβ17 5′-CAC AGA TAG TAA ATG ACT TTC AG-3′ 137 J Vβ18 5′-GAG TCA GGA ATG CCA AAG GAA-3′ 117 A Vβ19 5′-CCC CAA GAA CGC ACC CTG C-3′ 79 K Vβ20 5′-TCT GAG GTG CCC CAG AAT CTC-3′ 111 E Vβ21 5′-GAT ATG AGA ATG AGG AAG CAG-3′ 143 L Vβ22 5′-CAG AGA AGT CTG AAA TAT TCG A-3′ 122 F Vβ23 5′-TCA TTT CGT TTT ATG AAA AGA TGC-3′ 146 A Vβ24 5′-AAA GAT TTT AAC AAT GAA GCA GAC-3′ 129 K Cβ14 5′-CTC AGC TCC ACG TG-3′ CβR 5′-CTT CTG ATG GCT CAA ACA C-3′ a A total of 12 reaction sets (A—L) with two or more primers were used for multiplex PCR, as described in Materials and Methods.
- Table III.
Immunological and virological characteristics and lymphoproliferative responses of patients with major/minor or single/none pattern of CD8 clonal dominance
Major + Minor (n = 12) Single + None (n = 10) p Values Age (yr) 6.8 ± 4.4 9.8 ± 3.2 NS V.L. (log10)a 4.1 ± 1.1 4.8 ± 0.7 NS % CD4 28.3 ± 11.6 8.6 ± 4.8 <0.001 % CD8 38.3 ± 10.1 47.5 ± 15.5 NS DR+CD38+b 37.4 ± 13.1 54.6 ± 14.2 <0.01 LPA PHA 400.2 ± 518.5 258.4 ± 144.7 NS Candida 92.0 ± 59.5 12.3 ± 14.4 0.002 Tetanus 76.3 ± 51.2 11.2 ± 12.7 0.002 MLC 178.3 ± 298.9 32.9 ± 35.2 <0.001 a V.L. = Plasma HIV RNA (log10)
b Expressed as % CD8 cells.
In this issue
